Regen BioPharma Statistics
Total Valuation
Regen BioPharma has a market cap or net worth of 1.10 million. The enterprise value is 1.90 million.
| Market Cap | 1.10M |
| Enterprise Value | 1.90M |
Important Dates
The last earnings date was Thursday, April 17, 2025.
| Earnings Date | Apr 17, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Regen BioPharma has 21.55 million shares outstanding. The number of shares has increased by 16.21% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 21.55M |
| Shares Change (YoY) | +16.21% |
| Shares Change (QoQ) | +7.22% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | n/a |
| Float | 21.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.67 |
| PB Ratio | -0.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.19 |
| EV / Sales | 8.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -98.40% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 8.05% |
| Revenue Per Employee | 236,560 |
| Profits Per Employee | -867,252 |
| Employee Count | 1 |
| Asset Turnover | 0.89 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.69% in the last 52 weeks. The beta is 3.03, so Regen BioPharma's price volatility has been higher than the market average.
| Beta (5Y) | 3.03 |
| 52-Week Price Change | -92.69% |
| 50-Day Moving Average | 0.06 |
| 200-Day Moving Average | 0.18 |
| Relative Strength Index (RSI) | 48.81 |
| Average Volume (20 Days) | 12,187 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, Regen BioPharma had revenue of 236,560 and -867,252 in losses. Loss per share was -0.11.
| Revenue | 236,560 |
| Gross Profit | 236,560 |
| Operating Income | -418,189 |
| Pretax Income | -867,252 |
| Net Income | -867,252 |
| EBITDA | n/a |
| EBIT | -418,189 |
| Loss Per Share | -0.11 |
Balance Sheet
The company has 716 in cash and 794,699 in debt, giving a net cash position of -793,983 or -0.04 per share.
| Cash & Cash Equivalents | 716 |
| Total Debt | 794,699 |
| Net Cash | -793,983 |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -5.19M |
| Book Value Per Share | -0.49 |
| Working Capital | -5.21M |
Cash Flow
| Operating Cash Flow | -693,141 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -176.78% |
| Pretax Margin | -366.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | -176.78% |
| FCF Margin | n/a |
Dividends & Yields
Regen BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.21% |
| Shareholder Yield | -16.21% |
| Earnings Yield | -78.58% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on November 4, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Nov 4, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Regen BioPharma has an Altman Z-Score of -203.79. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -203.79 |
| Piotroski F-Score | n/a |